Ironwood Pharmaceuticals, Inc. (IRWD)
NASDAQ: IRWD · Real-Time Price · USD
3.230
+0.100 (3.19%)
At close: Dec 22, 2025, 4:00 PM EST
3.170
-0.060 (-1.86%)
After-hours: Dec 22, 2025, 7:56 PM EST
Ironwood Pharmaceuticals Revenue
Ironwood Pharmaceuticals had revenue of $122.06M in the quarter ending September 30, 2025, with 33.26% growth. This brings the company's revenue in the last twelve months to $338.99M, down -10.42% year-over-year. In the year 2024, Ironwood Pharmaceuticals had annual revenue of $351.41M, down -20.63%.
Revenue (ttm)
$338.99M
Revenue Growth
-10.42%
P/S Ratio
1.54
Revenue / Employee
$1,339,870
Employees
253
Market Cap
525.45M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 351.41M | -91.33M | -20.63% |
| Dec 31, 2023 | 442.74M | 32.14M | 7.83% |
| Dec 31, 2022 | 410.60M | -3.16M | -0.76% |
| Dec 31, 2021 | 413.75M | 24.23M | 6.22% |
| Dec 31, 2020 | 389.52M | -38.89M | -9.08% |
| Dec 31, 2019 | 428.41M | 81.77M | 23.59% |
| Dec 31, 2018 | 346.64M | 48.36M | 16.21% |
| Dec 31, 2017 | 298.28M | 24.32M | 8.88% |
| Dec 31, 2016 | 273.96M | 124.40M | 83.18% |
| Dec 31, 2015 | 149.56M | 73.12M | 95.66% |
| Dec 31, 2014 | 76.44M | 53.56M | 234.06% |
| Dec 31, 2013 | 22.88M | -127.36M | -84.77% |
| Dec 31, 2012 | 150.25M | 84.37M | 128.09% |
| Dec 31, 2011 | 65.87M | 22.01M | 50.19% |
| Dec 31, 2010 | 43.86M | 9.54M | 27.78% |
| Dec 31, 2009 | 34.32M | 15.94M | 86.70% |
| Dec 31, 2008 | 18.38M | 7.92M | 75.68% |
| Dec 31, 2007 | 10.46M | 7.32M | 233.25% |
| Dec 31, 2006 | 3.14M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
IRWD News
- 26 days ago - Ironwood Pharmaceuticals: Today's Gains Seem Sustainable After Disastrous First Half Of 2025 - Seeking Alpha
- 6 weeks ago - Ironwood Pharmaceuticals Reports Strong Third Quarter 2025 Results; Raises Full Year 2025 Financial Guidance - Business Wire
- 2 months ago - Ironwood Stair & Rail Inc. Recognised With 2025 Consumer Choice Award for Stairs and Railings in Southern Alberta - Accesswire
- 4 months ago - Ironwood Pharmaceuticals Reports Second Quarter 2025 Results; Maintains Full Year 2025 Financial Guidance - Business Wire
- 8 months ago - Ironwood Pharmaceuticals Reports First Quarter 2025 Results - Business Wire
- 8 months ago - Ironwood Pharmaceuticals to Participate in The Citizens Life Sciences Conference - Business Wire
- 8 months ago - Ironwood Pharmaceuticals Reiterates Full-Year 2025 LINZESS U.S. Net Sales Guidance and Raises Adjusted EBITDA Guidance - Business Wire
- 8 months ago - Ironwood Pharmaceuticals to Present Real-World Data at Digestive Disease Week® 2025 on Adoption of New Diagnosis Codes Among Short Bowel Syndrome Patients Who Are Dependent on Parenteral Support - Business Wire